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Carcinogenicity of EBDCs
In 1997 we published an article in EHP on
cytogenetic and thyroid hormonal changes
in 49 heavily exposed workers applying eth-
ylene bisdithiocarbamate (EBDC) fungicide
to tomatoes, based on a collaborative study
done by the U.S. National Institute for
Occupational Safety and Health and the
Institute of Public Health in Mexico
(Steenland et al. 1997). EBDCs are a com-
mon class of fungicides (e.g., mancozeb,
maneb) that are metabolized to ethylene
thiourea (ETU) in workers after primarily
dermal absorption. In experiments in rats,
ETU caused decreased thyroid hormone
[thyroxine (T4)], increased thyroid-stimulat-
ing hormone (TSH), and thyroid tumors.
We sought to determine whether workers
exposed to ETU showed thyroid hormone
changes compared to a nonexposed compar-
ison group (n = 31). We also looked at sister
chromatid exchange (SCE) and chromoso-
mal translocations (balanced chromosomal
aberrations that are not cell lethal) in the
lymphocytes of exposed workers and non-
exposed controls. 
In this study (Steenland et al. 1997), we
found a mean urinary ETU level in the
exposed applicators of 58 ppb, although
34% had levels below the limit of detection
(most ETU is excreted within 24 hr). All 31
nonexposed controls had levels below the
limit of detection. We found a significant
increase in TSH (p = 0.05) in applicators
versus nonexposed controls, suggesting that
increased TSH compensated for a thyroid
hormone decrease (altered homeostasis). We
also found increased SCEs (p = 0.03) and
chromosomal translocations (p = 0.05) in
the applicators versus the nonexposed popu-
lation, suggesting cytogenetic damage due
to ETU.
Subsequently, in 2001 the International
Agency for Research on Cancer (IARC)
downgraded ETU from group 2B (possibly
carcinogenic to humans) to group 3 (not
classifiable as to carcinogenicity in humans)
(IARC 2001). Although IARC recognized
that ETU was carcinogenic in animals, it
judged that the mechanism by which cancer
occurred in animals was not relevant to
humans. Specifically, IARC (2001) stated
that cancer occurred via a 
… nongenotoxic mechanism, which involves
interference with the functioning of thyroid perox-
idase resulting in a reduction of circulating thyroid
hormone concentrations and increased secretion of
thyroid-stimulating hormone. Consequently, ETU
would not be expected to produce thyroid cancer
in humans exposed to concentrations that do not
alter thyroid hormone homeostasis.
The use of mechanisms as a basis for classi-
fying or reclassifying agents as carcinogens
has been controversial, sometime leading to
upward classifications (ethylene oxide and
TCDD), but more often to downward ones
(e.g., ETU, atrazine, phthalates, saccharin)
(Tomatis 2002).
The IARC ETU working group (IARC
2001) cited our article (Steenland et al.
1997) as indicating cytogenetic damage in
workers “presumably” exposed to ETU
(apparently discounting the urinary evi-
dence). With regard to our findings of
increased TSH, indicative of altered thyroid
hormone homeostasis in ETU-exposed
workers, they noted that the workers had a
“marginal increase in the serum concentra-
tion of TSH but no change in that of thy-
roxine (T4).” As noted above, the “marginal”
increase was statistically significant, albeit not
clinically important (and normal T4 due to
increased TSH might be expected). The
working group chose to ignore this evidence
of altered homeostasis (IARC 2001).
It seems surprising that the IARC work-
ing group downgraded ETU based on a
lack of evidence that ETU alters thyroid
homeostasis in humans, while the only
study that has looked at this question in
humans did indeed find such evidence.
I would like to bring this apparent dis-
crepancy to the attention of the environ-
mental health community and to sound a
cautionary note regarding the possible
human carcinogencity of EBDC fungi-
cides, which are used extensively through-
out the world. In the United States, the
U.S. Environmental Protection Agency can-
celled the use in 1992 of EBDC fungicides
on 11 crops due to the evidence of animal
carcinogenicity but continues to permit
their use on a wide variety of nut, fruit, and
vegetable crops. 
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Carcinogenicity of EBDCs:
Response
The  IARC  (International Agency for
Research on Cancer) Monographs on the
Evaluation of Carcinogenic Risks to Humans
deal with all kinds of agents and exposures in
the human environment that may present a
cancer hazard. As of October 2002 (Volume
84), the program has evaluated 888 agents
and exposures, including ethylene thiourea
(ETU) recently (IARC 2001) and some of
the ethylene bisdithiocarbamate (EBDC)
fungicides earlier. The monographs do not
formally evaluate the carcinogenicity of
metabolites or other endogenously formed
substances, although evidence on the biologi-
cal activity of metabolites may provide
important supporting data for evaluating the
carcinogenicity of parent substances. The
monographs evaluated ETU as a primary
environmental exposure (IARC 2001).
Monograph working groups, which are
composed of independent scientific experts,
must follow the criteria set forth in the
“Preamble” to the monographs (IARC
1992) when making overall evaluations of
carcinogenicity to humans. Those criteria are
refined from time to time. In 1992 (when
Lorenzo Tomatis was director of IARC) the
definition of Group 3—not classifiable as to
carcinogenicity to humans—was modified as
follows (IARC 1992):
This category is used most commonly for agents,
mixtures and exposure circumstances for which
the evidence of carcinogenicity is inadequate in
humans and inadequate or limited in experimen-
tal animals. Exceptionally, agents (mixtures) for
which the evidence of carcinogenicity is inadequate
in humans but sufficient in experimental animals
may be placed in this category when there is strong
evidence that the mechanism of carcinogenicity in
experimental animals does not operate in humans.
[italics added]. Agents, mixtures and exposure cir-
cumstances that do not fall into any other group
are also placed in this category.
This definition has not changed since it was
first established in 1992. It is the responsi-
bility of individual working groups to
decide when the italicized criterion applies. 
The Monographs Programme has con-
vened several scientific workshops to address
certain modes of carcinogenic action in
experimental animals and to develop criteria
for assessing the roles of mechanistic evi-
dence in establishing overall evaluations of
carcinogenicity. The proceedings of these
workshops have been published, and the
consensus reports from these publications
are made available as guidance to mono-
graph working groups and are also freely
available on the monographs website (IARC
2003). Mechanisms of action of agents that
cause thyroid follicular cell tumors in experi-
mental animals have been studied exten-
sively and include both genotoxic and
nongenotoxic processes; these mechanisms
have been specifically addressed in several
papers in Capen et al. (1999). 
Thyroid follicular cell neoplasms are com-
monly seen in bioassays for carcinogenicity in
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the predictive value of rodent thyroid tumors
for human cancer hazard is whether data are
adequate to exclude a genotoxic mode of
action. These tumors are readily induced by
many genotoxic carcinogens, but they may
also be induced by virtually any nongenotoxic
goitrogen in these rodent species. In this
respect rodents and humans are quite differ-
ent. Human thyroid cancers are not exactly
comparable to the follicular cell tumors of
rats and mice, and no nonradioactive chemi-
cal is known to cause these cancers in
humans. The only clearly established cause of
thyroid cancers in humans is ionizing radia-
tion, especially in childhood (Ron 1996).
Occupational exposures to EBDCs can-
not be simply equated to exposure to ETU.
Occupational exposure to EBDCs entails
exposures to the parent compound(s) plus
other ingredients of the working formula-
tions used in agriculture, as well as to
endogenously formed ETU and other
metabolites, and is not identical to environ-
mental exposure to ETU per se. The 1997
study by Steenland et al. concerns a group
of workers using a mixture of different pes-
ticides, such as EBDC fungicides, organo-
phosphates (in “a typical mixture” up to
48% by weight), plant-regulating sub-
stances, and foliar nutrients (Steenland et
al. 1997). As the authors themselves indi-
cate, this paper reported on a single field
study with limited sample size; the results
are limited to subclinical outcomes (all thy-
roid hormone data being within the normal
range); and the data are of borderline statis-
tical significance and should be interpreted
with caution. The working group for IARC
Monograph Volume 79 (2001) did justice
to the paper by mentioning it as they did. 
Steenland’s assertion that mechanistic
information has been used more often by
monograph working groups to reach lower
overall evaluations of carcinogenicity—to
“downgrade” rather than “upgrade”—is
incorrect. Of the 888 overall evaluations of
carcinogenicity made since 1972, only a
small fraction have been based on what the
monographs refer to as “other relevant
data,” including mechanisms of carcino-
genicity. “Upgrades” include 5 from Group
2A to Group 1; 38 from Group 2B to
Group 2A; and 6 from Group 3 to Group
2B, a total of 49. Only 8 substances—< 1%
of the total—are “downgrades” from Group
2B to Group 3 on the basis of mechanistic
information, and only 3 of these substances
are thyrotropic chemicals. Anyone can go to
the lists of evaluations that are given on the
monographs website (IARC 2003) and con-
firm this. Overall evaluations that rely in
part on “other relevant data” bear a notation
to that effect. 
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Comment on “Use of 
A-Bomb Survivor Studies 
as a Basis for Nuclear Worker
Compensation”
I read with interest the letter of Wing and
Richardson (2002), which raised concerns
about using cancer risks derived from the Life
Span Study (LSS) cohort of Japanese atomic-
bomb survivor data in radiation worker com-
pensation plans. Wing and Richardson
(2002) criticized the methods of dose assess-
ment for the LSS data and implied that there
is significant dose misclassification in this
data set. They also stated that the atomic-
bomb survivors exhibit dose- and age-related
selective survival, citing recent work of
Stewart and Kneale (2000). They also
implied that there is inconsistency between
the cancer risks observed in the LSS and their
variation with age, and those observed in cer-
tain occupationally and medically exposed
groups. In this letter, I will show that these
criticisms of the LSS are without foundation.
There are random and systematic uncer-
tainties in the dose estimates in the LSS, as
are also found in most occupationally
exposed groups. Errors in dose assignments
in the LSS arise from uncertainties in the
location of survivors and those associated
with shielding by neighboring structures
(Jablon 1971; Roesch 1987). Uncertainties
in dose estimates in the worker cohorts are
caused by sampling variation in measure-
ments from film badges and thermolumines-
cent dosimeters, adjustments made to doses
below the limit of detection, and attenuation
of externally measured dose by shielding
(Gilbert 1998; Gilbert and Fix 1995). The
errors in the Japanese dose estimates are
thought to be log-normal with a geometric
standard deviation of about 30% (Jablon
1971); the dosimetric errors in the radiation
workers are of the same order (Kite and
Britcher 1996). The National Council on
Radiation Protection and Measurements
(NCRP 1997) concluded that accounting
for random and systematic errors in the LSS
results in reduction in the cancer mortality
risk coefficient by a factor of 0.84 [90% sub-
jective confidence interval (CI), 0.69–1.0].
Although the overall effect of dosimetric
errors on cancer risk coefficients derived
from the LSS is slight, it is well recognized
that such errors can substantially alter the
evidence for modification of the cancer dose
response by acute injury status (Little 2002a;
Neriishi et al. 1991). Stewart and Kneale
(2000) found significant differences of
excess relative risk (ERR) in the LSS for
leukemia and other end points, between sur-
vivors with two or more acute injuries and
survivors not having any acute injuries, but
did not take into account dosimetric errors.
Little (2002a) analyzed the same data and
showed that the findings of Stewart and
Kneale (2000) largely disappeared if proper
account was taken of dosimetric errors.
Stewart and Kneale (2000) also found
significant heterogeneity in ERR by age
group for various disease end points, which
they used to argue for the delayed effects of
acute injury in “vulnerable” age groups in the
LSS. Wing and Richardson (2002) also high-
lighted this decrease of ERR at older ages in
the LSS compared with the enhanced sensi-
tivity at older ages observed in some worker
cohorts. However, these findings in the LSS
are commonly observed in many medically
exposed groups [United Nations Scientific
Committee on the Effects of Atomic
Radiation (UNSCEAR) 2000]. Various
mechanistic models of carcinogenesis (Little
1995, 1996; Little et al. 1992) imply a
reduction of ERR with increasing age at
exposure. That these patterns are observed in
many different populations suggests that the
hypothesis proposed by Stewart and Kneale
(2000) and Wing and Richardson (2002) to
account for their occurrence in the LSS is
unlikely to be correct.
The risks observed in the LSS are gener-
ally statistically consistent with those
observed in occupationally (Cardis et al.
1995; Muirhead et al. 1999) and medically
exposed groups (Little and Boice 1999; Little
et al. 1999; UNSCEAR 2000). For example,
Muirhead et al. (1999) estimated that the
ratio of the leukemia ERR coefficient in
U.K. nuclear workers to that in the LSS is
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sponding ratio for all malignant neoplasms
excluding leukemia and lung cancer is 0.89
(90% CI, < 0–3.65). The ratio of lung can-
cer risk coefficients in the LSS and in groups
of underground miners is close to the value
suggested by the latest International
Commission on Radiological Protection
(ICRP 1994) model of lung dosimetry
(Birchall and James 1994; Little 2002b). The
general consistency of risks in the LSS and in
medically and occupationally exposed groups
implies that there are no serious biases in the
LSS dosimetry.
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Re: “Use of A-Bomb Survivor
Studies as a Basis for Nuclear
Worker Compensation”
Wing and Richardson (2002) suggested that
it is inappropriate to apply radiation risk esti-
mates derived from the follow-up of the
Japanese atomic-bomb survivors to persons
exposed chronically to low doses of radia-
tion. They referred to a paper I co-authored
(Doll and Wakeford 1997) in support of
their claim that a raised risk of childhood
cancer was not detected among the Japanese
survivors irradiated in utero, in contrast to
the elevated risk found in case–control stud-
ies of antenatal exposure to diagnostic X rays.
In fact, only just over 750 Japanese children
were exposed in utero during the atomic
bombings of Hiroshima and Nagasaki, and
two cases of childhood cancer were observed
in this cohort against an expected number of,
at most, 0.43 (Doll and Wakeford 1997;
Yoshimoto et al. 1988). These limited data
do indicate an excess risk of childhood can-
cer following intrauterine irradiation during
the bombings; the pertinent question is
whether the risk coefficient (risk per unit
dose) that may be derived from the Japanese
cohort study is compatible with the risk esti-
mates that may be obtained from the find-
ings of the case–control studies of fetal
exposure (Boice and Miller 1999; Doll and
Wakeford 1997; Wakeford 1995).
By far the largest case–control study of
childhood cancer and antenatal radiographic
examinations is the Oxford Survey of
Childhood Cancers (Bithell and Stewart
1975). A highly statistically significant
excess relative risk (ERR) associated with a
diagnostic X-ray examination of 40% was
obtained from the Oxford Survey, but reli-
able estimates of fetal doses appropriate for
this study are not easily derived (Mole 1990).
Bithell (1993) obtained an ERR coefficient
from the Oxford data of 51 per sievert, but
he believed that the uncertainty of this 
estimate could be as much as an order of 
magnitude. Further, Wakeford and Little (In
press) suggest that there are good reasons
from the Oxford data for believing that this
risk estimate may be a systematic overesti-
mate by perhaps as much as a factor of four.
In comparison, the Japanese data for in utero
irradiation provide an ERR coefficient for
childhood cancer of 23 per sievert, although,
again, the uncertainty of this estimate is large
(Delongchamp et al. 1997). The ERR coeffi-
cient derived from the Japanese cohort is only
of marginal statistical significance, but the
limited data available from this source must
be emphasized. Once proper account has
been taken of the uncertainties present in the
analyses of both data sets, it cannot reason-
ably be concluded that risk estimates are
incompatible (Wakeford and Little. In press).
The case–control studies of childhood
cancer and fetal X-ray exposure are impor-
tant because they demonstrate an excess risk
associated with doses near 10 mSv, doses an
order of magnitude below those received in
other epidemiologic studies showing an
excess risk of cancer following irradiation
(UNSCEAR 2000). The interpretation of
the findings of these case–control studies has
been questioned (Boice and Miller 1999),
but Doll and Wakeford (1997) believed that
the available evidence provides strong
grounds for a causal explanation of the asso-
ciation. However, the point estimates of risk
obtained from a comparatively small ERR in
the face of many uncertainties should not be
overinterpreted, and it cannot be claimed
with any confidence that the risk coefficient
derived from the Oxford Survey is dis-
crepant with that derived from the limited
data from the Japanese survivors exposed in
utero (Wakeford and Little. In press). I sus-
pect that Wing and Richardson (2002) have
been overoptimistic in the accuracy that
they have assigned to two risk estimates that
superficially appear to suit their argument.
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CORRECTIONS
In the article by Wilhelm and Ritz [Environ Health Perspect 111:207–216 (2003)], a
negative sign was omitted from the equation on page 208. The correct equation appears
below. EHP regrets the error.
Li et al. [EHP 111:455–460 (2003)] would like to thank Arantzazu Eiguren-Fernandez and
Antonio H. Miguel of the Southern California Particle Center and Supersite (Los Angeles,
CA, USA) for their analyses of polycyclic aromatic hydrocarbons, elemental carbon, and
organic carbon reported in “Ultrafine Particulate Pollutants Induce Oxidative Stress and
Mitochondrial Damage,” published in the April issue of EHP. Their data is a valuable
contribution to the article.
In “Atrazine-Induced Hermaphroditism at 0.1 ppb in American Leopard Frogs (Rana pipiens):
Laboratory and Field Evidence” by Hayes et al. [Environ Health Perspect 111:568–575
(2003)], Figure 8 was incorrect. The correct figure appears below:
Figure 8. Gonads from a treated male
R. pipiens (0.1 ppb atrazine) with vitel-
logenic testicular oocytes. (A) Bouin’s-
fixed section; bar = 250 µm. The posterior
portion of the gonad is filled with oocytes
that are protruding through the testicular
lobules and can be seen on the surface of
the gonad; white arrows show areas
where transverse cross-sections were
taken. (B) Transverse cross-sections
showing that the anterior testis has poorly
developed testicular lobules; the black
arrowhead shows a tangentially sectioned
oocyte. (C) and (D) Large vitellogenic
oocytes in the posterior portion of the
gonads. Bar = 250 µm for panels (B–D). See
“Materials and Methods” for details of
histological analysis. 
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